United Therapeutics UTHR Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| Adcirca | $2.9M-51.7% | $7.8M+66.0% | $9.7M+38.6% | $6.5M+14.0% | $6M-6.3% | |
| Nebulized Tyvaso | $127.2M-22.3% | $125.7M-11.9% | $141.8M-10.9% | $154.4M+10.4% | $163.8M+13.0% | |
| Orenitram | $135.6M+12.3% | $121.2M+12.4% | $131.1M+15.8% | $123.9M+15.7% | $120.7M+13.7% | |
| Remodulin | $126.6M-8.4% | $128M-4.8% | $125.9M-1.9% | $134.7M-8.6% | $138.2M+8.0% | |
| Tyvaso DPI | $330.3M+9.2% | $338.6M+23.9% | $336.2M+22.4% | $315.2M+22.0% | $302.5M+33.0% | |
| Unituxin | $53.6M-7.9% | $62.3M-7.7% | $47.9M-21.6% | $58.4M+13.0% | $58.2M-0.3% | |
| Gross Profit by Product | ||||||
| Adcirca | $1.9M-44.1% | $4.4M+51.7% | $5.3M+35.9% | $3.8M+22.6% | $3.4M-10.5% | |
| Nebulized Tyvaso | $118.6M-23.6% | $119.3M-11.8% | $135.1M-9.8% | $148.8M+13.2% | $155.3M+14.1% | |
| Orenitram | $128.2M+14.1% | $114.3M+11.9% | $124.3M+17.7% | $117.2M+15.8% | $112.4M+15.9% | |
| Remodulin | $110.5M-11.2% | $119.9M-1.0% | $112.8M-1.9% | $120.4M-10.5% | $124.4M+3.6% | |
| Tyvaso DPI | $247.1M-2.9% | $279.9M+19.2% | $280.9M+19.3% | $266.7M+20.8% | $254.4M+31.0% | |
| Unituxin | $48.6M-8.3% | $56.4M-13.6% | $44.3M-21.3% | $55.6M+16.1% | $53M-3.3% | |
| Cost of Sales by Product | ||||||
| Adcirca | $1M-61.5% | $3.4M+88.9% | $4.4M+41.9% | $2.7M+3.8% | $2.6M0.0% | |
| Nebulized Tyvaso | $8.6M+1.2% | $6.4M-13.5% | $6.7M-28.7% | $5.6M-33.3% | $8.5M-4.5% | |
| Orenitram | $7.4M-10.8% | $6.9M+21.1% | $6.8M-10.5% | $6.7M+13.6% | $8.3M-9.8% | |
| Remodulin | $16.1M+16.7% | $8.1M-39.6% | $13.1M-1.5% | $14.3M+11.7% | $13.8M+74.7% | |
| Tyvaso DPI | $83.2M+73.0% | $58.7M+52.9% | $55.3M+41.4% | $48.5M+29.0% | $48.1M+44.4% | |
| Unituxin | $5M-3.8% | $5.9M+168% | $3.6M-25.0% | $2.8M-26.3% | $5.2M+44.4% | |
| Total revenues by Geography | ||||||
| ROW | $37.3M-16.7% | $37.4M+23.8% | $24.7M-21.8% | $38.8M-2.3% | $44.8M+23.8% | |
| U.S. | $744.2M-0.7% | $752.8M+6.7% | $774.8M+8.0% | $759.8M+12.5% | $749.6M+16.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does United Therapeutics break its business down?
- United Therapeutics (UTHR) reports total revenues by product across 6 parts — Adcirca, Nebulized Tyvaso, Orenitram, Remodulin and Tyvaso DPI. Each is extracted from the segment footnotes and tracked over time.
- Where does United Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in United Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
